



Medical Coverage Policy

Effective Date3/15/2026

Next Review Date3/15/2027

Coverage Policy Number..... 0539

Peripheral Nerve Stimulation and Peripheral Nerve Field Stimulation

Table of Contents

Overview	2
Coverage Policy	2
Coding Information	2
General Background.....	4
Health Equity Considerations.....	18
Medicare Coverage Determinations	19
References.....	19
Revision Details.....	25

Related Coverage Resources

- [Electric Stimulation for Pain, Swelling and Function in a Clinic Setting](#)
- [Electrical Stimulation Therapy and Devices in a Home Setting](#)
- [Gastric Pacing/Gastric Electrical Stimulation \(GES\)](#)
- [Headache, Occipital, and/or Trigeminal Neuralgia Treatment](#)
- [Peripheral Nerve Destruction for Pain Conditions](#)
- [Sacral Nerve Stimulation for Urinary Voiding Dysfunction, Fecal Incontinence and Constipation](#)
- [Spinal Cord and Dorsal Root Ganglion Stimulation](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request

should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses implantable peripheral nerve stimulation (PNS) and peripheral nerve field stimulation (PNFS) for the treatment of pain conditions.

For the use of electrical stimulation in the treatment of headache, occipital, or trigeminal neuralgia, see Cigna Medical Coverage policy "Headache, Occipital, and/or Trigeminal Neuralgia Treatment".

For the use of sacral nerve stimulation (SNS) for the treatment of fecal incontinence and urinary conditions, see Cigna Medical Coverage policy "Sacral Nerve Stimulation for Urinary Voiding Dysfunction, Fecal Incontinence and Constipation".

Coverage Policy

Implantable peripheral nerve stimulation (PNS) for the treatment of acute or chronic pain conditions is considered not medically necessary.

Implantable peripheral nerve field stimulation (PNFS) is considered experimental, investigational or unproven for any indication.

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Not Medically Necessary for the treatment of acute or chronic pain conditions:

CPT®* Codes	Description
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)
64999 [†]	Unlisted procedure, nervous system

†Note: Considered Experimental, Investigational or Unproven when used to report implantable peripheral nerve field stimulation (PNFS).

HCPCS Codes	Description
C1767 [†]	Generator, neurostimulator (implantable), non-rechargeable
C1778 [†]	Lead, neurostimulator (implantable)
C1787 [†]	Patient programmer, neurostimulator
C1816 [†]	Receiver and/or transmitter, neurostimulator (implantable)
C1820 [†]	Generator, neurostimulator (implantable), with rechargeable battery and charging system
C1822 [†]	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
C1883 [†]	Adaptor/extension, pacing lead or neurostimulator lead (implantable)
C1897 [†]	Lead, neurostimulator test kit (implantable)
C9807 [†]	Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)
L8679 [†]	Implantable neurostimulator, pulse generator, any type
L8680 [†]	Implantable neurostimulator electrode, each
L8681 [†]	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8682 [†]	Implantable neurostimulator radiofrequency receiver
L8683 [†]	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
L8685 [†]	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
L8686 [†]	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8687 [†]	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
L8688 [†]	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension

HCPCS Codes	Description
L8689 [†]	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only
L8695 [†]	External recharging system for battery (external) for use with implantable neurostimulator, replacement only

†Note: Considered Experimental, Investigational or Unproven when submitted with implantable peripheral nerve field stimulation (PNFS).

***Current Procedural Terminology (CPT®) ©2025 American Medical Association: Chicago, IL.**

General Background

Peripheral Nerve Stimulation (PNS)

Implantable peripheral nerve stimulation (PNS) for the treatment of pain conditions involves the implantation of electrodes on or near a peripheral nerve which has been identified as transmitting pain to a specific area of the body. PNS has been proposed for the treatment of chronic pain that is not responsive to conservative treatments. Chronic pain conditions for which PNS has been proposed include: hemiplegic shoulder pain, back pain, carpal tunnel syndrome; causalgia, complex regional pain syndrome, failed back syndrome, fibromyalgia, hemiplegic shoulder pain, brachial plexus injuries, post-trauma pain, subacromial impingement syndrome, post-amputation pain, postherpetic neuralgia, stroke, testicular pain, and trigeminal neuropathy (International Neuromodulation Society [INS], 2019; Reverberi, et al., 2014; Stevanato, et al., 2014; Wilson, et al., 2014; Stidd, et al., 2012).

Chronic pain is a significant public health concern in the United States, affecting nearly one in four adults. According to the National Health Interview Survey (NHIS), 24.3% of U.S. adults reported chronic pain in the past three months, with 8.5% experiencing high-impact chronic pain that limits daily activities. Back pain is particularly common, with 39.0% of adults reporting back pain and 30.7% reporting upper limb pain (including shoulder and arm pain) within the same period (Lucas and Sohi, 2024; Lucas, et al., 2021).

Peripheral nerve stimulation (PNS) delivers repetitive electrical stimulation to nerves involved in pain production or transmission, with the goal of modulating and reducing pain signaling. Although the exact mechanisms are not fully understood, conventional PNS (e.g., SPRINT PNS System, StimRouter Neuromodulation System) is theorized to alter nociceptive input and decrease pain perception; its effects are typically dependent on continued stimulation and symptoms may return when therapy is discontinued (Slavin, 2022).

PNS systems include a neurostimulator (pulse generator), leads (thin wires with electrodes), a controller (remote control device that allows the patient to control the device), and a programmer that is a remote control device that allows a medical professional to make adjustments to the settings of the pulse generator. The leads are positioned and connected to the generator. PNS procedures are usually performed in stages, wherein electrodes are first implanted for trialing purposes prior to permanent implantation of the generator. If the trial is deemed successful (usually defined as >50% response rate in pain reduction), the generator and/or electrodes are permanently implanted in the chest, abdomen or buttocks.

U.S. Food and Drug Administration (FDA): Implantable peripheral nerve stimulators for the treatment of pain conditions currently approved or cleared by the FDA are regulated as either

Class II or III medical devices. These devices are approved through the Premarket Notification 510(k) regulatory pathway. Across FDA-cleared and approved implantable peripheral nerve stimulation devices, the shared indications for use center on providing pain relief through electrical stimulation of peripheral nerves. These systems are generally intended for the management of chronic or intractable pain conditions.

Examples of FDA-approved implantable peripheral nerve stimulators for pain relief include:

Device or Product	Identifier	Manufacturer
Freedom® Peripheral Nerve Stimulator (PNS) System	K233162	Curonix
Moventis PNS	K200848	Micron Medical Corporation
Nalu Neurostimulation System	K232415	Nalu Medical, Inc.
Neuspera Neurostimulation System	K202781	Neuspera Medical Inc.
SPRINT PNS System	K223306	SPR Therapeutics
StimRouter Neuromodulation System	K211965	Bioness Inc.
TalisMann Neuromodulation System	K243678	Bioventus LLC

*FDA product codes: GZF, NHI, QLK

Note: Coverage decisions are not based solely on FDA approval. Device or product names are provided for example purposes only. Their inclusion does not indicate endorsement or preference for any specific brand or model. This list is not intended to reflect all available products or technologies.

Literature Review: There is insufficient evidence in the published peer-reviewed literature to support the safety and effectiveness of implanted peripheral nerve stimulation for the treatment of acute or chronic pain conditions. The existing body of evidence consists of systematic reviews, systematic reviews and meta-analyses of RCTs, RCTs, retrospective analyses, and several case series and cohort studies.

Across the published peer-reviewed literature evaluating this technology, key limitations include manufacturer sponsorship and participant compensation, reliance on a recall-based PGIC measure, small patient populations, short-term follow-up, variable treatment parameters, lack of a control group, selection and attrition bias from including only enrolled patients with complete data, and the absence of information on concurrent treatments or medication adjustments that may confound interpretation of clinical benefit. Systematic reviews and meta-analysis consistently report on the lack of high-quality RCTs and heterogeneity among studies which precludes meta-analysis. There remains poor understanding of the underlying mechanisms of PNS, appropriate patient selection, or long-term outcomes of therapy (Engle, et al., 2025; Hatheway, et al., 2025; Manchikanti, et al., 2025; Goree, et al., 2024; Hatheway, et al., 2024a; Hatheway, et al., 2024b; Abd-Elsayed and Moghim, 2023; Chou, et al., 2021; Helm, et al., 2021; Xu, et al., 2021; Deer, et al., 2020; Cohen, et al., 2019; Gilmore, et al., 2019a; Gilmore, et al., 2019b; Gilmore, et al., 2019c; Oswald, et al., 2019; Wilson et al., 2017; Deer, et al., 2016; Reverberi, et al., 2014; Wilson, et al., 2014).

Engle et al. (2025) conducted a randomized controlled trial (COMFORT 2) to evaluate a micro-implantable pulse generator peripheral nerve stimulation system (Nalu Neurostimulation System) for chronic pain of peripheral nerve origin among adults aged 18–80 years treated at 18 U.S. sites. Subjects were randomized in a 2:1 ratio to active peripheral nerve stimulation plus conventional medical management (n=109) versus conventional medical management alone (n=64), with control subjects allowed to cross over at three months. Key inclusion criteria

required chronic pain for at least six months localized to the knee, shoulder, low back, or foot/ankle. Major exclusions included complex regional pain syndrome, metabolic or postherpetic neuralgia, ≥ 90 mg morphine equivalents per 24 hours, failure of psychological screening, or inability to use the system. The primary outcome was pain intensity by the Brief Pain Inventory question 5 Numeric Rating Scale. Secondary outcomes included Patient Global Impression of Change, Brief Pain Inventory–Short Form, EQ-5D-5L, Beck Depression Inventory, Oswestry Disability Index, along with safety, satisfaction, device comfort, usability, and compliance. Patient-reported outcomes were collected at one, three, and six months. Twelve subjects exited due to failed trials and were excluded from the modified intention-to-treat population. At three months, the active arm achieved an 80% responder rate with 66% mean pain reduction ($p < 0.001$) versus 4% responders and 3% pain reduction in controls, with statistically significant improvements across secondary endpoints. At six months, the active arm responder rate was 79% with 64% mean pain reduction. “Non-serious” adverse events resolved without sequelae, and including lead migrations, implantable pulse generator issues requiring revisions, infections (some requiring explant), and two explants for inefficacy or magnetic resonance imaging compatibility. Authors identified limitations included lack of a blinded sham control, the three-month cross-over, and variability in conventional medical management availability. Additional limitations included the short-term follow-up, participant attrition, small patient population, and the fact that participants continued their existing conventional medical management throughout the study, creating the possibility that improvements in pain may have been influenced in part by ongoing medical therapy rather than the intervention alone.

In a systematic review and meta-analysis, Manchikanti et al. (2025) evaluated randomized controlled trials of peripheral nerve stimulation for chronic pain and including RCTs with minimum follow-up duration of six months for implanted systems. Across nine included RCTs, interventions encompassed implanted PNS and temporary 60-day systems, with comparators such as deactivated stimulation, sham stimulation, and conventional medical management. The primary outcome was the proportion of patients achieving significant pain relief and functional improvement ($\geq 50\%$). Follow-up time points emphasized 1, 3, 6, and 12 months, with some trials extending to multi-year durability. Attrition was variably reported across included RCTs. Quantitative synthesis reported statistically significant improvements for several time points and outcomes (e.g., pooled ORs and MDs with P -values ≤ 0.05). Adverse events ranged from nonserious in some trials to high rates requiring surgical revision in others. Limitations included scarcity of high-quality studies, heterogeneity of instruments and follow-up time points, short-term follow-up, overall evidence rating of “fair”, high attrition rates, and lack of a true placebo.

Hatheway et al. (2024a and 2024b) conducted a randomized controlled trial ($n=89$) to evaluate peripheral nerve stimulation (PNS) with a micro-implantable pulse generator (micro-IPG; Nalu Neurostimulation System) (COMFORT trial) for the treatment of chronic peripheral pain. Fifty-eight subjects were randomized to the Nalu treatment group, and 31 to the control group. Those in the Nalu group received PNS and conventional medical management (CMM) throughout the trial. Subjects in the control group received CMM alone for three months, at which time 24 subjects crossed over to the Nalu group. The inclusion criteria were age 18-80; chronic, intractable post-surgical/post-traumatic peripheral pain/neuralgia, mononeuropathy, other neuralgia or neuropathic pain, or osteoarthritic pain, affecting of the lower back, shoulder, knee or foot/ankle; pain score of at least six and exclusive of the craniofacial region; and currently on CMM stable pain medication use/dosage for 30 days. Exclusion criteria included an active implantable medical device; previously failed PNS, spinal cord stimulation, or dorsal root ganglion therapy; pain absent at rest; complex regional pain syndrome, peripheral neuralgia of metabolic origin, post-herpetic neuralgia, metabolic or genetic neuropathy; successful interventional procedure within prior three months to treat the same pain condition(s); uncontrolled depression or psychiatric disorders; pending/ongoing legal issues or conflicting secondary gain issues related to chronic pain condition; coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease; active

systemic infection; active malignancy or paraneoplastic syndrome; uncontrolled diabetes; alcohol or drug dependency within prior six months; pregnancy; nursing/breastfeeding; on ≥ 90 mg-morphine equivalents per 24 hours; and prior ablative treatments. The primary outcome measure was the numeric rating scale (NRS) pain score from the target area of peripheral pain. Secondary outcome measures included the Patient Global Impression of Change (PGIC), Brief Pain Inventory Short Form (BPI-SF), quality-of-life metric (EuroQoL [EQ-5D-5L]), Beck Depression Inventory (BDI) and Oswestry Disability Index (ODI). Follow ups were completed at three, six, and twelve months. Sixty one subjects (69%) completed the 12-month follow up. A modified-intention-to-treat analysis was performed. At three and six months, subjects in the Nalu group achieved a 67% and 70% improvement in pain, respectively, compared with baseline ($p < 0.001$). The control group achieved a 6% improvement in pain at three months. At 12 months, the responder rate was 87% (53/61) with an average pain reduction of 69%. Mean pain scores (NRS) improved from 7.5 ± 1.20 at baseline to 2.3 ± 1.7 at 12 months. For PGIC, 48% (29/61) reported very much improved, 44% (27/61) reported much improved, 3% (2/61) reported minimally improved, and 5% (3/61) reported no change. At 12 months, 93% (57/61) of subjects reported continued use of oral medications and 20% (12/61) using topical applications for pain. Adverse events included generator migrations, lead migrations, lead fractures, infections, and wound complications. Revisions and explanations/device discontinuation were needed in some cases. Limitations of the study included lack of participant blinding, heterogeneity of CMM protocols, 31% drop out rate/loss to follow up, race/ethnicity data was not reported, and device usage/compliance was not addressed. The study was sponsored by Nalu Medical.

Deer et al. (2020) conducted a systematic review of 14 RCTs ($n=20-157$) which evaluated peripheral nerve stimulation (PNS) or peripheral nerve field stimulation (PNFS) for the treatment of pain. Indications for treatment included headache (six studies, $n=389$), shoulder pain (two studies, $n=50$), leg and/or back pain (four studies, $n=306$), and pelvic pain (three studies, $n=146$). Included in the review were RCTs evaluating PNS or PNFS in patients with intractable pain. Excluded were retrospective studies and RCTs with less than two months of follow-up. The primary outcome measure was improvement in pain. Intervention and duration of treatment varied widely, as did comparators (e.g., "usual care", physical therapy, sham treatment). Follow ups ranged from three months to one year (median seven months). Due to the heterogeneity of patient populations, diagnoses, interventions, comparators, outcome measures, and study designs, a quantitative meta-analysis was not completed. The authors concluded that several studies indicated occipital nerve stimulation can be beneficial for chronic migraine, medication overuse headache, and intractable chronic migraine; there was moderate evidence that implanted sphenopalatine ganglion stimulation is effective for cluster headaches; there was strong evidence that PNFS is beneficial for patients with continued low back pain following surgery, medications, and/or interventional pain procedures; there was moderate evidence that implanted PNS can provide at least modest improvements in mononeuropathic pain and hemiplegic shoulder pain; and fair evidence that peripheral tibial nerve stimulation (PTNS) may be helpful for overall pain, dyspareunia, and chronic pelvic pain. Many studies lacked a true control group and/or blinding. Other limitations of included studies were the relatively small sample sizes and short duration of follow-up.

Gilmore et al. (2019c) conducted a double-blinded, randomized, placebo-controlled study with 28 lower extremity amputees with postamputation neuropathic pain. The subjects underwent ultrasound-guided implantation of percutaneous PNS leads and were randomized to receive either peripheral nerve stimulation (PNS) with the SPRINT pulse generator (SPR Therapeutics), or placebo (sham stimulation) for four weeks. The placebo group then crossed over and all subjects received PNS for four additional weeks. The primary efficacy endpoint evaluated the proportion of subjects reporting $\geq 50\%$ pain reduction during one to four weeks. A greater proportion of subjects receiving PNS ($n=7/12$, 58%, $p=0.037$) demonstrated $\geq 50\%$ reductions in average postamputation pain during weeks one through four, compared with subjects receiving placebo

(n=2/14, 14%). Two subjects were excluded from efficacy analysis due to eligibility changes. Greater proportions of PNS subjects also reported $\geq 50\%$ reductions in pain (n=8/12, 67%, p=0.014) and pain interference (n=8/10, 80%, p=0.003) after eight weeks of therapy compared with subjects receiving placebo (pain: n=2/14, 14%; pain interference: n=2/13, 15%). Author-noted limitations of the study included the small number of subjects; partial crossover design; variation in lead replacement in the placebo group at time of crossover; and high variation in opioid use.

Gilmore et al. (2019b) reported on 12-month outcomes in the cohort in the above study (Gilmore, et al., 2019c). Nine participants from the PNS group (64% of the initial 14 participants) and six from the placebo group (43% of the original group of 14) were assessed at 12 months. It was noted that more participants in the PNS group reported $\geq 50\%$ reductions in average weekly pain at 12 months (67%, 6 of 9 subjects) compared with the placebo at the end of the placebo period (0%, 0/14, p=0.001). In addition, 56% (5 of 9) participants in the PNS group reported $\geq 50\%$ reductions in pain interference at 12 months, compared with 2/13 (15%, p=0.074) in the original placebo group at crossover. Limitations of the study included the small number of subjects and considerable loss to follow up (46%).

Deer et al. (2016) conducted a prospective, multicenter, randomized, double-blind, partial crossover study to assess the safety and efficacy of the StimRouter System for the treatment of severe, intractable peripheral nerve pain associated with posttraumatic or postsurgical neuralgia. Ninety-four patients were randomized to the treatment group (n=45) or the control group (n=49). Primary outcomes included pain relief (measured by average pain at rest using a numerical rating scale [NRS]) over three months' time; and safety, (determined by assessment of adverse events [AEs]) during the one-year study period. The treatment group received electrical stimulation from the StimRouter System and stable dosing of pain medications, while the control group received no therapeutic stimulation and a stable dose of pain medications. At three months, patients in the treatment group achieved a higher response rate of 38% vs. the 10% rate found in the control group (p=0.0048). The treatment group achieved a mean pain reduction of 27.2% from baseline to month three, compared to a 2.3% reduction in the control group (p<0.0001). There were no serious adverse events related to the device. For safety follow-up, 15 did not participate in the six- and 12-month follow-up and 33 patients at 12 month follow-up, representing an attrition of 51%.

Professional Societies/Organizations

American Society of Interventional Pain Physicians (ASIPP): In 2024, ASIPP published guidelines for the use of implantable peripheral nerve stimulation (PNS) for the management of chronic pain. The consensus statements were based on a literature review which included seven systematic reviews, eight randomized controlled trials, and nine observational studies covering all PNS treatments. The level of evidence for recommendations related to direct PNS interventions ranged from "Low" to "Fair", and the strength of those recommendations was rated as "Moderate". The recommendations included the following (Manchikanti, et al., 2024):

1. "There is evidence supporting the accuracy and value of diagnostic methods for diagnosing conditions amenable to peripheral nerve stimulation. Evidence Level: Low; Strength of Recommendation: Moderate
2. The evidence of effectiveness of peripheral nerve stimulation in managing chronic pain, based on evidence synthesis utilizing comprehensive and systematic review of the literature with methodologic quality assessment of all studies, applying GRADE criteria, and best evidence synthesis for implantable peripheral nerve stimulation systems following a trial or selective lumbar medial branch stimulation without a trial, is Level III or fair with moderate certainty utilizing GRADE criteria. Evidence Level: Fair; Strength of Recommendation: Moderate

3. The evidence of effectiveness of peripheral nerve stimulation in managing chronic pain based on evidence synthesis utilizing comprehensive and systematic review of the literature with methodologic quality assessment of all studies, applying GRADE criteria, and best evidence synthesis for implantable stimulation systems following temporary peripheral nerve stimulation for 60 days is Level III or fair with moderate certainty utilizing GRADE criteria. Evidence Level: Fair; Strength of Recommendation: Moderate
4. Based on the evidence and the recommendations, indications may be expanded from present CMS guidance with addition of craniofacial pain, phantom limb pain, and low back pain, either nociceptive or neuropathic, with present evidence showing Level III or fair with moderate certainty utilizing GRADE criteria. Evidence Level: Fair; Strength of Recommendation: Moderate
5. It is important to understand each type of peripheral nerve stimulation implant with features of the equipment and technical requirements. Evidence Level: Moderate; Strength of Recommendation: Strong
6. Based on the available evidence and all the available guidance, patient education is a crucial aspect of success of peripheral nerve stimulation. Evidence Level: Moderate; Strength of Recommendation: Strong
7. Risk stratification of peripheral nerve stimulation, based on ASIPP guidelines: low risk for peripheral nerve stimulation trial and implantation of extremities and other superficial nerves, moderate risk for lumbar medial branches and high risk for thoracic and cervical medial branches, trigeminal and cranial nerve blocks and nerve stimulation. Evidence Level: Moderate; Strength of Recommendation: Moderate
8. Antiplatelet and anticoagulant therapy guidelines in continuation, discontinuation, and re-establishment are utilized as per ASIPP guidelines for low- and high-risk procedures. Evidence Level: Moderate; Strength of Recommendation: Moderate”

American Society of Pain and Neuroscience (ASPN): In 2022, ASPN published guidelines on the use of implantable peripheral nerve stimulation (PNS) for the treatment of chronic pain. The investigating panel conducted a systematic review which included 20 randomized controlled trials (RCTs) and 33 prospective observational studies. The studies were heterogeneous in terms of pain conditions treated, including head and neck pain, peripheral neuropathies, back pain, post-amputation pain, among other conditions. The panel then appraised the evidence, developed recommendations, and stratified them by evidence level and degree of recommendation, as such:

Level of evidence and study hierarchy by design type	
I	At least one controlled and randomized clinical trial, properly designed
II-1	Well-designed, controlled, non-randomized clinical trials
II-2	Cohort or case studies and well-designed controls, multicenter preferable
II-3	Multiple series compared over time, with or without intervention, and surprising results in non-controlled experiences
III	Clinical experience-based opinions, descriptive studies, clinical observations, or reports of expert committee
Degree of recommendation	
A	Extremely recommendable (good evidence that the measure is effective and that benefits outweigh the harms)
B	Recommendable (at least moderate evidence that the measure is effective and that benefits exceed harms)

Level of evidence and study hierarchy by design type	
C	Neither recommendable nor inadvisable (at least moderate evidence that the measure is effective, but benefits are similar to harms and a general recommendation cannot be justified)
D	Inadvisable (at least moderate evidence that the measure is ineffective or that the harms exceed the benefits)
I	Insufficient, low-quality, or contradictory evidence; the balance between benefit and harms cannot be determined

Having applied the above grading system, ASPN presented the following best practices guidelines:

Guidelines	Level of Evidence	Grade
<ul style="list-style-type: none"> PNS may offer modest and short-term pain relief, improved physical function, and better quality of life for chronic hemiplegic shoulder pain. PNS may be considered for lower extremity neuropathic pain following failure of conservative treatment options and is associated with modest pain relief. PNS may be considered for lower extremity post-amputation pain following failure of conservative treatment options and is associated with modest to moderate pain relief. 	I	B
<ul style="list-style-type: none"> PNS for mononeuropathies of the upper extremity may be offered following a positive diagnostic ultrasound-guided nerve block of the targeted nerve and is associated with modest to moderate pain relief. There is evidence that PNS of lumbar medial branch nerves may improve pain intensity, physical function, and pain interference in patients with axial, mechanical low back pain. 	II-2	B
<ul style="list-style-type: none"> There is limited evidence that PNS may alleviate pain in neuropathic pain syndrome involving the trunk and back including radiculopathy and post-herpetic neuralgia. As a less-invasive modality compared to SCS therapy, PNS may be offered to patients with CRPS Type I or Type II, and may be associated with modest improvement in pain intensity and functional outcomes. However, high-quality evidence is limited and other neuromodulation interventions such as dorsal root ganglion SCS are recommended for CRPS. 	III	C

The authors noted PNS neuromodulation is a novel and emerging technology, and RCTs and/or large prospective observational trials are limited (Strand, et al., 2022).

In 2025, ASPN published three consensus guidelines that present an expert-opinion synthesis asserting evidence for PNS across numerous chronic pain indications, the use of 60-day PNS therapy, and the use of PNS for the treatment of non-surgical low back pain. However, several limitations of these guidelines exist. ASPN acknowledges that the mechanism of action of PNS remains uncertain and multifactorial, and calls for further research to clarify it; lead placement often occurs adjacent to mixed motor-sensory nerves and the ASPN notes the practical challenges (e.g., fiber selectivity, migration, erosion) that complicate consistent targeting and durable benefit. The publications provide limited safety characterization beyond listing known device-related complications (e.g., lead migration and erosion, infection) and do not present a comprehensive safety framework with rates stratified by indication, device, and follow-up duration. The guideline’s authors collectively disclose financial relationships with and support from multiple PNS manufacturers which introduce the potential for bias in evidence selection and the strength of recommendations. Additionally, the guidelines apply the USPSTF evidence grading scale—which is primarily designed for preventive services—rather than the GRADE system, which is widely considered the gold standard for evaluating the quality of evidence and strength of recommendations in clinical practice guidelines (Deer, et al., 2025; Gill, et al., 2025; Latif, et al., 2025).

Implantable Restorative Peripheral Nerve Field Stimulation

ReActiv8 is an implantable restorative neurostimulation system designed specifically for chronic mechanical low back pain associated with impaired control of the lumbar multifidus muscle. Unlike conventional peripheral nerve stimulation, which modulates sensory nerve activity to reduce pain perception, ReActiv8 delivers electrical stimulation to the medial branch nerve to activate and recondition the multifidus muscle. This approach aims to restore neuromuscular control and improve spinal stability over time. The device stimulates the nerves of the multifidus muscle, with the goal of interrupting the cycle of muscle inhibition, pain, and functional decline. Despite its restorative intent, ReActiv8 is not considered curative, as it does not reverse underlying degenerative spinal pathology (Mainstay Medical, 2026).

U.S. Food and Drug Administration (FDA): The ReActiv8 Implantable Neurostimulation System (Mainstay Medical, Brooklyn Center, MN) received FDA premarket (PMA) approval for the indication of “bilateral stimulation of the L2 medial branch of the dorsal ramus as it crosses the transverse process at L3 as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy and are not candidates for spine surgery.” Potential complications associated with the use of the ReActiv8 System include lead or implanted pulse generator (IPG) migration; skin erosion; persistent pain at lead or IPG sites; nerve or muscular damage; loss of pain relief over time; and ineffective pain control due to system component or battery issues.

Device or Product	Identifier	Manufacturer
ReActiv8 Implantable Neurostimulation System	P190021	Mainstay Medical Limited

*FDA product codes: QLK

Note: Coverage decisions are not based solely on FDA approval. Device or product names are provided for example purposes only. Their inclusion does not indicate endorsement or preference for any specific brand or model. This list is not intended to reflect all available products or technologies.

Literature Review: There is insufficient evidence in the published, peer-reviewed literature to support the safety and efficacy of implantable restorative peripheral nerve stimulation (PNS) for treating impaired control of the lumbar multifidus muscle. The current body of evidence includes

two randomized controlled trials, as well as cohort studies and case series. However, these studies are limited by small sample sizes, short-term follow-up, incomplete or variable reporting of treatment parameters, open-label designs, participant attrition, and the absence of control groups or comparison to standard treatment options. In addition, the risk of sponsorship bias is high due to manufacturer funding and disclosed financial conflicts of interest among investigators and authors (Huang, et al., 2025; Schwab, et al., 2025; Thomson, et al., 2025; Gilligan, et al., 2024; Gilligan, et al., 2023; Ardeshiri, et al., 2022; Deer, et al., 2021; Gilligan, et al., 2021a; Gilligan, et al., 2021b; Mitchell, et al., 2021; Deckers, et al., 2018; Gilmore, et al., 2018).

Huang et al. (2025) conducted a single-center study aimed at developing and implementing a clinical care pathway for restorative neurostimulation targeting the multifidus muscle in patients with chronic mechanical low back pain. The design comprised audits of attendance and outcomes alongside a prospective cross-sectional survey of patient satisfaction, enrolling 107 patients (58 female; mean age 58 years, range 27–83). The intervention was restorative neurostimulation delivered within a structured pathway with preoperative education and postoperative follow-up at days 14 and 45, and months 3, 6, 12, and 24; no control or comparator group was reported. Candidate identification and screening drew on criteria from prior ReActiv8 trials, with additional multidisciplinary assessments; explicit inclusion and exclusion lists were not reported. Primary outcomes were changes from baseline in low back pain numeric rating score and Oswestry Disability Index at 12 months or last assessment, categorical pain reductions, adverse events, and patient satisfaction. Across assessable patients, 77% achieved a minimally important clinical difference in either disability or pain; mean cohort ODI decreased from 38.9 to 24.7 at 12 months, and mean cohort pain scores decreased from 6.3 to 3.3. Satisfaction was high without statistically significant differences across time points; specific p values were not provided. Eight patients could not be assessed due to loss to follow-up, incomplete data, or device removal for infection or need for MRI. Reported adverse events included device/electrode removals for lack of efficacy, removals for imaging needs, one infection, and IPG pocket site revisions for discomfort. Author noted limitations included the absence of a comparator and lack of medication or quality-of-life measures.

Schwab et al. (2025) reported on the first-year outcomes of the RESTORE trial, a multicenter, open label randomized controlled trial which compared outcomes in individuals with chronic low back pain (CLBP) associated with multifidus dysfunction treated with restorative neurostimulation (Reactiv8) along with optimal medical management (OMM), versus a control group receiving OMM alone. All subjects received OMM, which included medications; non-pharmacological, physical, or psychosocial therapies; and more invasive interventions such as blocks and injections. Subjects randomized to the treatment group were also treated with ReActiv8. Subjects were instructed to initiate therapy daily over at least two sessions, for a maximum of 60 minutes per day. The study inclusion criteria were age over 21; lumbar multifidus muscle dysfunction; intractable CLBP rated 6-9 persisting over six months; failure of therapy; not a candidate for spinal surgery; Oswestry Disability Index (ODI) score ≥ 30 and ≤ 60 ; and on OMM. Exclusion criteria included a contraindication for the ReActiv8 system; BMI > 35 ; prior surgical correction for scoliosis or current moderate to severe scoliosis; known/suspected cause of CLBP amenable to surgery; worse leg pain than back pain; radiculopathy below the knee; previous back surgery at or below T8; previous thoracic or lumbar sympathectomy; lumbar medial branch rhizotomies within prior year; lumbar medial branch blocks within prior 30 days; past or current neuromodulation devices; pregnant or planning to be pregnant in the next year; muscle wasting, muscle atrophy, or progressive neurological disease; active disruptive psychological or psychiatric disorder; opioid addiction or drug-seeking behavior; active malignancy; active infection; poorly controlled diabetes; current smoking; condition requiring MRI or diathermy; life expectancy less than one year; and pending or approved financial compensation claim. The authors stated a minimum of 204 evaluable patients were needed to sufficiently power the primary endpoint. A total of 226 subjects were randomized; 23 subjects withdrew prior to follow up; 203 were included in the

modified intention-to-treat analysis; and 188 (83%) subjects completed the one year follow up. There was a statistically significant difference between the treatment and control groups in Depression Anxiety and Stress Scale (DASS) (5.3 ± 5.6 vs 7.1 ± 6.2 , respectively; $p=0.040$), and active depression (38% vs 62%, respectively; $p=0.029$). The primary outcome measure was mean change in the Oswestry Disability Index (ODI). Secondary outcome measures included change from baseline in average low back pain in the prior 24 hours, and change from baseline in quality of life using the EuroQol Five-Dimension Scale (EQ-5D-5L). At one year, the mean change in ODI between the treatment and control groups was statistically significant (-19.7 ± 1.4 vs -2.9 ± 1.4 ; between-group difference of 16.8 ± 1.9 ; 95% confidence interval [CI] [-20.6 to -13.0 points]; $p<0.001$). Secondary outcome measures were statistically significant in the treatment group versus the control group, for change in back pain (-3.6 ± 0.2 vs -0.6 ± 0.2 ; between-group difference of -3.0 ± 0.3 ; 95% CI [-3.6 , -2.5]; $p<0.001$) and change in healthcare-related EQ-5D-5L (0.155 ± 0.012 vs 0.008 ± 0.012 ; between-group difference of 0.147 ± 0.018 ; 95% CI [0.112 , 0.1821]; $p<0.001$). There were 31 device-, procedure-, and/or therapy-related adverse events in 23 treatment group subjects. These included implant site pocket pain and infection; device overstimulation; lead fracture; implant site seroma and dermatitis; anesthetic complications; delayed healing; aggravated back pain; radicular pain; shoulder pain; syncope; and wound infection. Eight ReActiv8 system modifications were performed in seven patients, and included explants; lead revisions; and implantable pulse generator pocket revision. Limitations of the study included the lack of participant blinding to treatment; loss to follow up; treatment adherence/compliance was not addressed; study was potentially underpowered; and race/ethnicity of the participants was not addressed. These are the reported one-year outcomes; subjects will be followed for an additional year. The study was funded by Mainstay Medical, Inc.

Gilligan et al. (2021a) reported on a randomized, double-blind, sham-controlled trial to determine safety and efficacy of an implantable, restorative neurostimulator (ReActiv8), designed to restore control of the multifidus muscle and facilitate relief of symptoms, namely low back pain (LBP). The study included 204 patients with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control. Subjects were implanted and randomized to therapeutic ($n=102$) or low-level sham ($n=102$) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions ($\geq 30\%$ relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through one year for long-term outcomes and adverse events. There was no comparative assessment at one year. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, -3.3% to 24.1%, $p=0.138$). Eight device- or procedure-related serious adverse events were reported in eight participants (4%), all before the 120-day follow-up. At the time of publication, participant follow-up was intended for a total of five years, to provide additional insights into the long-term benefits, risks, and reliability of the device.

Gilligan et al. (2021b) reported on the two-year outcomes of the ReActiv8 neurostimulator in patients with disabling chronic low back pain (CLBP) secondary to multifidus muscle dysfunction, and no indications for spine surgery (follow-up of above the Gilligan, et al., 2021a). Open-label follow-up of 204 participants implanted with the ReActiv8 restorative neurostimulation system was performed. Pain intensity (visual analog scale [VAS] in centimeters [cm]), disability (Oswestry disability index [ODI]), quality-of-life (EQ-5D-5L), and opioid intake were assessed at baseline, six months, one year, and two years after activation. A total of 156 participants (76%) were included in the two-year analysis. The proportion of participants with $\geq 50\%$ CLBP relief was 71%, and 65% reported CLBP resolution (VAS ≤ 2.5 cm); 61% had a reduction in ODI of ≥ 20 points, 76% had improvements of $\geq 50\%$ in VAS and/or ≥ 20 points in ODI, and 56% had these substantial

improvements in both VAS and ODI. A total of 87% of participants had continued device use during the second year for a median of 43% of the maximum duration, and 60% (34 of 57) had voluntarily discontinued (39%) or reduced (21%) opioid intake. Over the preceding two years, 45 participants (22%) had undergone a total of 47 surgical interventions, during which 32 systems were removed. Reasons for system removal included a lack of efficacy (n=18), infection (n=6), as a safety precaution before MRI (n=6), resolution of LBP (n=1), and relocation to a remote area without device follow-up infrastructure (n=1).

Gilligan et al. (2023) completed a three-year outcomes analysis of the above ReActiv8 trial (Gilligan, et al., 2021a), which included data on 133 participants (65% of the original cohort). Between the two- and three-year follow-up analyses, 17 patients withdrew for various reasons: seven had the ReActiv8 device explanted for inadequate response; six explanted for pain resolution; two were lost to follow-up; one explanted for MRI; and there was one unrelated death. By three years, the mean average low back pain (LBP) visual analog scale (VAS) score had improved by -4.9 ± 0.2 cm (95% confidence interval [CI], -5.3 to -4.5 ; $p < 0.0001$), and 100/130 (77%) of participants had a $\geq 50\%$ reduction in VAS; 80/130 (62%) of participants had a $\geq 70\%$ VAS reduction, and 87/130 (67%) had resolution of chronic low back pain (CLBP) (VAS ≤ 2.5 cm). The mean Oswestry Disability Index (ODI) score improved by -22.7 ± 1.3 (95% CI, -25.3 to -20.1 ; $p < 0.0001$), and 82/131 (63%) of participants had a ≥ 20 point ODI reduction. The proportion of participants with a reduction in LBP VAS of $\geq 50\%$ and/or ODI of ≥ 20 -points without an increase in either was 109/131 (83%). The proportion who exceeded these cut-offs in both VAS and ODI was 73/130 (56%). Of the participants with three-year follow-up data, 51/133 (38%) were taking opioids at baseline, and 36/51 (71%) had voluntarily discontinued (25/51 [49%]) or reduced (11/51 [22%]) opioid dosage. Over the three-year follow-up period, 25 devices were removed for inadequate response to ReActiv8 therapy, and seven were removed due to resolution of low back pain. No additional device or procedure-related serious adverse events were reported.

Gilligan et al. (2024) published the five-year outcomes of the above ReActiv8 trial (Gilligan, et al., 2021a), which included data on 126 participants (62% of the original cohort). At the five-year follow up, the mean average low back pain had improved from 7.3 ± 0.2 cm at baseline to 2.4 ± 0.2 cm ($-67.5\% \pm 3.1\%$ [95% confidence interval [CI] -73.5 to -61.5]; $p < 0.0001$); 89 of 124 participants (71.8%) had a reduction in visual analog scale (VAS) of $\geq 50\%$, and 83 of 124 (66.9%) had resolution of chronic low back pain (VAS of ≤ 2.5 cm). The mean Oswestry Disability Index (ODI) improved from 39.1 ± 10.3 points at baseline to 16.5 ± 1.3 (-22.7 ± 1.4 [95% CI -25.4 to -20.8]; $p < 0.0001$), and 77 of 126 participants (61.1%) had an ODI reduction of ≥ 20 . The mean EuroQol EQ-5D-5L index improved by 0.231 ± 0.018 (95% CI 0.195 - 0.267 ; $p < 0.0001$). Of the 52 subjects who were on an opioid-containing medication at baseline and had a five-year visit, 69% either discontinued (46%) or decreased (23%) intake. Over the five-year study, a total of 27 (13%) of participants had the device removed for inadequate pain response, while 18 participants (9%) had the device removed for resolution of low back pain (with a mean residual VAS of 2.3 ± 0.5 cm and ODI of 9.6 ± 2.2). Author-noted limitations included that the sham-control group was not maintained during long-term follow up, and direct correlations with objective device usage and multifidus structure/function were not made. The study was funded by Mainstay Medical, Inc.

Thomson et al. (2025) conducted a prospective, open-label, post market clinical follow-up study to evaluate five-year outcomes of restorative neurostimulation in a cohort of 42 adults, pulled from Gilligan et al.'s study above, with chronic mechanical low back pain associated with multifidus dysfunction, treated across five United Kingdom sites using the ReActiv8 system. Patients were selected per National Health Service guidelines, device instructions for use, and CE Mark indications, reflecting real-world practice without formal inclusion or exclusion criteria. Prior conservative therapies were attempted and a multidisciplinary team assessment was required. The

intervention consisted of an implanted system (i.e., ReActiv8) delivering stimulation to the medial branches of the L2 dorsal rami to restore multifidus activation; no control or comparator arm was included. Outcomes, including pain via Numerical Rating Scale; disability via Oswestry Disability Index; health-related quality of life via EQ-5D-5L; and device utilization via implant logs, were assessed at baseline, at specified intervals through one year, and annually thereafter to five years. At five years, 34 of 42 patients (81%) completed follow-up; attrition included explants for inadequate pain relief, two lost to follow-up, one explant for MRI need (no longer required under updated device conditionality), one death unrelated to study, and one missed final visit. Reported results demonstrated improvements in pain, disability, and quality of life, including mean NRS reductions from 7.0 to 3.2, mean ODI reductions from 46.6 to 26.1, EQ-5D increases from 0.426 to 0.703, 82%. Statistical significance was reported in narrative form for all outcome measures however, specific statistical data for individual outcomes was not provided. Safety reporting indicated no serious adverse events during years four and five and one instance of tissue overstimulation was resolved via reprogramming. Author identified limitations included the open-label design and the lack of a control arm. Additional limitations included: small patient population, missing data due to COVID 19 impacts that was later estimated based on usage patterns prior to the data gap; attrition, and heterogeneity of usage/treatment parameters. The study was funded by Mainstay Medical, Inc.

Deckers et al. (2018) conducted a prospective single arm trial to evaluate restorative neurostimulation of the lumbar multifidus using the ReActiv8 device, for the treatment of chronic mechanical low back pain (CMLBP) in patients who failed conventional therapy and were not candidates for surgery or spinal cord stimulation (SCS). The study included fifty-three patients who were implanted with the ReActiv8 neurostimulator. Leads were positioned bilaterally with electrodes close to the medial branch of the L2 dorsal ramus nerve. The primary outcome measure was low back pain evaluated on a 10-Point Numerical Rating Scale (NRS). Responders were defined as subjects with an improvement of at least the Minimal Clinically Important Difference (MCID) of ≥ 2 -points in low back pain NRS without a clinically meaningful increase in LBP medications at 90 days. Secondary outcome measures included Oswestry Disability Index (ODI) and Quality of Life (QoL; EQ-5D). For 53 subjects with an average duration of CLBP of 14 years and average NRS of 7 and for whom no other therapies had provided satisfactory pain relief, the responder rate was 58%. The percentage of subjects at 90 days, six months, and one year with \geq MCID improvement in single day NRS was 63%, 61%, and 57%, respectively. Percentage of subjects with \geq MCID improvement in ODI was 52%, 57%, and 60% while those with \geq MCID improvement in EQ-5D was 88%, 82%, and 81%. There were no unanticipated or serious adverse events related to the device, procedure, or therapy. The initial surgical approach led to a risk of lead fracture, which was mitigated by a modification to the surgical approach. Potential limitations of the study included the small number of patients, lack of randomization, and lack of a control group.

Mitchell et al. (2021) reported on the four-year results of the above study (Deckers, et al., 2018); data was available on 33 patients (62% of the original cohort). Subjects reported mean scores (\pm standard error of the mean): low back pain Numeric Rating Scale (NRS) of 3.2 ± 0.4 ; Oswestry Disability Index (ODI) score of 23.0 ± 3.2 ; and European Quality of Life Score on Five Dimensions (EQ-5D) score of 0.721 ± 0.035 ; indicating mean improvements from baseline were statistically significant ($p < 0.001$). Seventy-three percent of participants had a clinically meaningful improvement of ≥ 2 points on NRS; 76% of ≥ 10 points on ODI; and 62.5% had a clinically meaningful improvement in both NRS and ODI. The authors noted the high dropout rate and relatively high lead revision rate may have impacted reported outcomes.

Professional Societies/Organizations

International Society for the Advancement of Spine Surgery (ISASS): In a 2023 statement, ISASS stated restorative neurostimulation should be considered for clinically appropriate patients with chronic mechanical low back pain who have exhausted reasonable conservative approaches. ISASS noted that a limited number of studies was available for review, and that industry funding is a potential source of bias (Lorio, et al., 2023). In 2025, the ISASS issued an updated guideline reaffirming its support for coverage of implantable restorative neurostimulation (e.g., ReActiv8) for chronic low back pain associated with multifidus dysfunction in a subset of individuals >18 years of age who have failed ≥ 6 months of conservative management and no clear indications for spine surgery. This reaffirmation is based on 5-year follow-up, reproducibility in two randomized controlled trials, and four real-world evidence studies (Lorio, et al., 2025).

Peripheral Nerve Field Stimulation (PNFS)

Peripheral nerve field stimulation (PNFS), also known as subcutaneous peripheral field stimulation, subcutaneous nerve stimulation, or subcutaneous target stimulation (STS), has been proposed for the treatment of chronic cervical, thoracic, or lumbar pain. Electrode leads are placed in subcutaneous tissue around the painful area, and electrical current is applied to create stimulation in the area, or "field" of pain. This technique is different from peripheral nerve stimulation (PNS), in which specific, visible, and identifiable peripheral nerves are targeted. In peripheral nerve field stimulation, many smaller unnamed, nonspecific nerves are targeted. The electrodes are placed in the skin either through an open or percutaneous approach. Imaging guidance is included, when performed. The electrode is placed subcutaneously at the site of maximum pain rather than at the site of the nerve. This technique involves a temporary trial period for approximately two to 14 days. A trial may be considered "successful" if there is at least a 50% reduction in pain. Following a successful temporary trial, the device is implanted. The most common complications associated with PNFS include lead migration, skin erosion, and infection (Barolat, 2018). The role of PNFS in the management of pain conditions has not been established.

Literature Review: Comparative controlled trial data evaluating PNFS in the published, peer-reviewed scientific literature are limited, and there is currently insufficient evidence to determine safety and effectiveness of this treatment. Evidence is primarily in the form of case series, retrospective reviews, and studies with small patient populations (Eldabe, et al., 2019; Ishak, et al., 2018; Mitchell, et al., 2016; Petersen, et al., 2014; McRoberts, et al., 2013; Verrills, et al., 2011).

Eldabe et al. (2019) conducted the SubQStim randomized controlled trial (RCT) (n=116) to compare the effectiveness of peripheral nerve field stimulation/subcutaneous nerve stimulation (SQS) plus optimized medical management (OMM), versus OMM alone in individuals with back pain due to failed back surgery syndrome (FBSS). Subjects in the SQS+OMM group (n=56) underwent a trial period with subcutaneous lead placement in the area of pain, connected to an external neurostimulator. A successful trial was defined as back pain reduction of > 30% as measured by visual analog scale (VAS), as some reduction in pain along with improved function or quality of life, or as a reduction in pain medication use. Subjects could titrate stimulation as necessary for pain relief. OMM for each subject was defined by the investigator, and varied by type, frequency, duration, and/or dose. Forty five subjects had leads permanently implanted. The control group (n=60) received OMM only. Included in the study were adults with FBSS (i.e., persistent pain for six months following most recent back surgery, no further therapeutic surgical options, and intractable back pain). Excluded from the study were individuals with prior or current implantable neurostimulation or intrathecal drug delivery system; active disruptive psychiatric disorder; any severe pain condition unrelated to FBSS; spinal fusion > three vertebral levels; or history of coagulation disorder or lupus erythematosus. The primary outcome was responder rate (defined as $\geq 50\%$ reduction in back pain intensity from baseline) at nine months. Secondary outcome measures included pain intensity, functional disability using the Oswestry Disability Index

(ODI), quality of life, healthcare utilization, pain medication use, and safety (at 36 months). The study was terminated early by the sponsor; 74 subjects completed the nine-month primary endpoint visit. At nine months, the responder rate in the SQS+OMM arm was 33.9% (n=19; 95% confidence interval [CI] [21.5–46.3%]) compared to 1.7% (n=1; 95% CI [0.0–4.9%]) in the OMM group (p<0.0001). There were 193 events reported up to the 36-month visit (103 in SQS+OMM, 90 in OMM); 15 were device-related. Limitations of the study included lack of blinding; variation in lead type and placement, device programming parameters, and degree of stimulation; variation in OMM treatment; missing data; and subjects had already failed OMM upon enrollment, thus a significant improvement in the OMM group was unlikely.

Ishak et al. (2018) conducted a study to assess the usefulness, safety and efficacy of subcutaneous peripheral nerve field stimulation (SPNS) in patients with chronic low back pain (CLBP). Twenty-six consecutive patients with CLBP were prospectively enrolled in the study. Two electrodes were implanted vertically at a depth of one cm into the subcutaneous tissue, ≤ 10 cm from the region of maximum pain. Trial neurostimulation was performed in all patients for 14 days. A successful outcome was defined as at least 50% pain relief. To evaluate the effects of permanent neurostimulation, the Visual Analog Scale (VAS), the Oswestry Disability Index (ODI), and quality of life (EQ-5D-3L) were scored preoperatively and at six-month and 24-month follow-ups. Thirteen patients responded to trial stimulation and had a permanent neurostimulator implanted. The use of pain medication, including opioid analgesics, was reduced in 92% of patients after 24 months. VAS, ODI, and EQ-5D-3L scores were improved in these patients at the 24-month follow-up. The complication rate was 23% (3/13 patients). In non-responders, the VAS and ODI at 24 months dropped as well but the decrease was less pronounced compared to responders and did not lead to decrease in pain medication. The study was limited by small number of participants and lack of randomization. Large prospective, randomized, controlled studies are needed to confirm findings.

Professional Societies/Organizations

American Society of Pain and Neuroscience (ASPN): In 2022, ASPN published guidelines on the use of implantable peripheral nerve stimulation (PNS) for the treatment of chronic pain. The investigating panel conducted a systematic review which included 20 randomized controlled trials (RCTs) and 33 prospective observational studies. The studies were heterogeneous in terms of pain conditions treated, including head and neck pain, peripheral neuropathies, back pain, post-amputation pain, among other conditions. The panel then appraised the evidence, developed recommendations, and stratified them by evidence level and degree of recommendation, as such:

Level of evidence and study hierarchy by design type	
I	At least one controlled and randomized clinical trial, properly designed
II-1	Well-designed, controlled, non-randomized clinical trials
II-2	Cohort or case studies and well-designed controls, multicenter preferable
II-3	Multiple series compared over time, with or without intervention, and surprising results in non-controlled experiences
III	Clinical experience-based opinions, descriptive studies, clinical observations, or reports of expert committee
Degree of recommendation	
A	Extremely recommendable (good evidence that the measure is effective and that benefits outweigh the harms)

Level of evidence and study hierarchy by design type	
B	Recommendable (at least moderate evidence that the measure is effective and that benefits exceed harms)
C	Neither recommendable nor inadvisable (at least moderate evidence that the measure is effective, but benefits are similar to harms and a general recommendation cannot be justified)
D	Inadvisable (at least moderate evidence that the measure is ineffective or that the harms exceed the benefits)
I	Insufficient, low-quality, or contradictory evidence; the balance between benefit and harms cannot be determined

Having applied the above grading system, ASPN presented the following best practices guidelines:

Guidelines	Level of Evidence	Grade
<ul style="list-style-type: none"> Subcutaneous peripheral field stimulation and optimal medication management may offer moderate improvement in pain intensity for failed back surgery compared to optimal medication management alone. 	I	B

The authors noted PNS neuromodulation is a novel and emerging technology, and RCTs and/or large prospective observational trials are limited (Strand, et al., 2022).

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation, and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

Using a nationally representative household survey of U.S. civilian noninstitutionalized adults (National Health Interview Survey), Lucas and Sohi (2024) reported that in 2023, 24.3% of adults had chronic pain and 8.5% had high-impact chronic pain. Women had higher percentages than men for both chronic pain and high-impact chronic pain. Percentages increased with age for both outcomes, with the highest values among adults aged 65 years and older. By race and Hispanic origin, American Indian and Alaska Native adults showed higher percentages for chronic and high-impact chronic pain compared with Asian adults; Asian adults had the lowest percentages across groups. The report identified a gradient by urbanization level: percentages increased from large central metropolitan to nonmetropolitan areas for both chronic pain and high-impact chronic pain. Socioeconomic status and insurance coverage were not reported.

In another National Health Interview Survey, Lucas et al. (2021) reported that 58.9% experienced any pain in the past 3 months; site-specific prevalence was 39.0% for back pain, 36.5% for lower limb pain, and 30.7% for upper limb pain. Prevalence increased with age and was higher among

women compared with men across locations. By race and Hispanic origin, non-Hispanic White adults had the highest percentages and non-Hispanic Asian adults the lowest. Pain prevalence decreased with increasing family income as a percentage of the federal poverty level. Geography and insurance coverage were not reported.

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	Electrical Nerve Stimulators (160.7)	8/7/1995
LCD	National	Assessing Patient's Suitability for Electrical Nerve Stimulation Therapy (160.7.1)	6/19/2006
LCD	Noridian Healthcare Solutions, LLC	Peripheral Nerve Stimulation (L34328; L37360)	12/1/2019

Note: Please review the current Medicare Policy for the most up-to-date information. (NCD = National Coverage Determination; LCD = Local Coverage Determination)

References

1. Abd-Elsayed A, Moghim R. Efficacy of Peripheral Nerve Stimulation with a High Frequency Electromagnetic Coupled (HF-EMC) Powered Implanted Receiver in Treating Different Pain Targets/Neuralgias. *J Pain Res.* 2023 Feb 23;16:589-596.
2. Ardeshiri A, Amann M, Thomson S, Gilligan CJ. Application of restorative neurostimulation for chronic mechanical low back pain in an older population with 2-year follow up. *Reg Anesth Pain Med.* 2025 Mar 5;50(3):231-236.
3. Ardeshiri A, Shaffrey C, Stein KP, Sandalcioglu IE. Real-World Evidence for Restorative Neurostimulation in Chronic Low Back Pain-a Consecutive Cohort Study. *World Neurosurg.* 2022 Dec;168:e253-e259.
4. Barolat G. Peripheral Nerve Field Stimulation for Intractable Pain. In: Krames ES, Peckham PH, Rezai AR. *Neuromodulation.* 2nd ed. Cambridge, MA: Elsevier; 2018. 763-771.
5. Centers for Medicare and Medicaid Services (CMS). Medicare Coverage Database. Accessed Dec 19, 2025. Available at URL address: <https://www.cms.gov/medicare-coverage-database/search.aspx>
6. Chou R, Fu R, Dana T, Pappas M, Hart E, Mauer KM. *Interventional Treatments for Acute and Chronic Pain: Systematic Review [Internet].* Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. Report No.: 21-EHC030.
7. Cohen S, Gilmore C, Kapural L, Hanling S, Plunkett A, McGee M, Boggs J. Percutaneous Peripheral Nerve Stimulation for Pain Reduction and Improvements in Functional Outcomes in Chronic Low Back Pain. *Mil Med.* 2019 Mar 1;184(Suppl 1):537-541.
8. Copley S, Batterham A, Shah A, Foly A, Hagedorn JM, Deer T, Gilligan C, Eldabe S. Systematic Review and Meta-analysis of Stimulation of the Medial Branch of the Lumbar Dorsal Rami for the Treatment of Chronic Low Back Pain. *Neuromodulation.* 2024 Dec;27(8):1285-1293.

9. Deckers K, De Smedt K, Mitchell B, Vivian D, Russo M, Georgius P, et al. New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial. *Neuromodulation*. 2018 Jan;21(1):48-55.
10. Deer TR, Esposito MF, McRoberts WP, Grider JS, Sayed D, Verrills P, Lamer TJ, Hunter CW, Slavin KV, Shah JM, Hagedorn JM, Simopoulos T, Gonzalez DA, Amirdelfan K, Jain S, Yang A, Aiyer R, Antony A, Azeem N, Levy RM, Mekhail N. A Systematic Literature Review of Peripheral Nerve Stimulation Therapies for the Treatment of Pain. *Pain Med*. 2020 Aug 1;21(8):1590-1603.
11. Deer TR, Gilmore CA, Desai MJ, Li SC, DePalma MJ, Hopkins TJ, Burgher AH, Spinner DA, Cohen SP, McGee MJ, Boggs JW. Percutaneous Peripheral Nerve Stimulation of the Medial Branch Nerves for the Treatment of Chronic Axial Back Pain in Patients After Radiofrequency Ablation. *Pain Med*. 2021 Mar 18;22(3):548-560.
12. Deer T, Pope J, Benyamin R, Vallejo R, Friedman A, Caraway D, et al. Prospective, Multicenter, Randomized, Double-Blinded, Partial Crossover Study to Assess the Safety and Efficacy of the Novel Neuromodulation System in the Treatment of Patients With Chronic Pain of Peripheral Nerve Origin. *Neuromodulation*. 2016 Jan;19(1):91-100.
13. Deer TR, Pope JE, Petersen EA, Abdallah RT, Amirdelfan K, Azeem N, Bansal V, Barkoh K, Chapman KB, Denis DR, Dorsi MJ, Escobar A, Falowski SM, Garcia RA, Hagedorn JM, Heros RD, James WS, Kalia H, Lansford T, Malinowski MN, Manzi SM, Mehta P, Moghim RZ, Moore GA, Motivala SL, Navalgund YA, Patel RG, Pilitsis JG, Schatman ME, Shumsky PM, Strand NH, Tomycz ND, Yue JJ, Sayed D. An Evidence-Based Consensus for the Use of Neurostimulation for the Treatment of Non-Surgical Low Back Pain: The NEURON Group. *J Pain Res*. 2025 Mar 14;18:1247-1274. doi: 10.2147/JPR.S500342. PMID: 40104824; PMCID: PMC11917438.
14. Eldabe SS, Taylor RS, Goossens S, Bouche B, Gültuna I, Green C, Tinsley J, Luyet PP, Buchser E. A Randomized Controlled Trial of Subcutaneous Nerve Stimulation for Back Pain Due to Failed Back Surgery Syndrome: The SubQStim Study. *Neuromodulation*. 2019 Jul;22(5):519-528.
15. Engle M, Gutierrez G, Hersel A, Netzel C, Khemlani V, et al. A confirmatory randomized controlled trial evaluating a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 3- and 6-month results from the COMFORT 2 study. *Chron Pain Manag*. 2025;9:171. doi:10.29011/2576-957X.100071.
16. Gill B, Tidwell C, Hagedorn JM, Moreira AM, Lawandy M, Boyett B, Schappell J, Latif U, Pritzlaff S, Skaribas I, Kalia H, Sheth S, Schnur M, Li S, Lester D, Ellico T, Naidu R, Russo D, Massey C, Ottestad E, Vorenkamp K, Vucetic H, Pingree MJ, Abejón D, Desai MJ, Dickerson D, Gulati A, Sayed D, Deer TR. Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project. *J Pain Res*. 2025 Jun 24;18:3117-3139. doi: 10.2147/JPR.S521788. PMID: 40590046; PMCID: PMC12206896.
17. Gilmore CA, Kapural L, McGee MJ, Boggs JW. Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Chronic Low Back Pain Provides Sustained Relief. *Neuromodulation*. 2018 Oct 3.

18. Gilmore CA, Kapural L, McGee MJ, Boggs JW. Percutaneous Peripheral Nerve Stimulation for Chronic Low Back Pain: Prospective Case Series With 1 Year of Sustained Relief Following Short-Term Implant. *Pain Pract.* 2019a Nov 6.
19. Gilmore CA, Ilfeld BM, Rosenow JM, Li S, Desai MJ, Hunter CW, Rauck RL, et al. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial. *Reg Anesth Pain Med.* 2019b Nov 17.
20. Gilmore C, Ilfeld B, Rosenow J, Li S, Desai M, Hunter C, et al. Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial. *Reg Anesth Pain Med.* 2019c Jun;44(6):637-645.
21. Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, et al.; ReActiv8-B Investigators. Long-Term Outcomes of Restorative Neurostimulation in Patients With Refractory Chronic Low Back Pain Secondary to Multifidus Dysfunction: Two-Year Results of the ReActiv8-B Pivotal Trial. *Neuromodulation.* 2021b Dec 18:S1094-7159(21)06386-8.
22. Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, et al; ReActiv8-B investigators. An implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial. *Pain.* 2021a Oct 1;162(10):2486-2498.
23. Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, Deckers K, De Smedt K, Latif U, Sayed D, Georgius P, Gentile J, Mitchell B, Langhorst M, Huygen F, Baranidharan G, Patel V, Mironer E, Ross E, Carayannopoulos A, Hayek S, Gulve A, Van Buyten JP, Tohmeh A, Fischgrund J, Lad S, Ahadian F, Deer T, Klemme W, Rauck R, Rathmell J, Maislin G, Heemels JP, Eldabe S. Five-Year Longitudinal Follow-Up of Restorative Neurostimulation Shows Durability of Effectiveness in Patients With Refractory Chronic Low Back Pain Associated With Multifidus Muscle Dysfunction. *Neuromodulation.* 2024 Jul;27(5):930-943.
24. Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, Deckers K, De Smedt K, Latif U, Sayed D, Georgius P, Gentile J, Mitchell B, Langhorst M, Huygen F, Baranidharan G, Patel V, Mironer E, Ross E, Carayannopoulos A, Hayek S, Gulve A, Van Buyten JP, Tohmeh A, Fischgrund J, Lad S, Ahadian F, Deer T, Klemme W, Rauck R, Rathmell J, Schwab F, Maislin G, Heemels JP, Eldabe S. Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction. *Neuromodulation.* 2023 Jan;26(1):98-108. Epub 2022 Sep 27. Erratum in: *Neuromodulation.* 2023 Aug;26(6):1272-1273.
25. Goree JH, Grant SA, Dickerson DM, Ilfeld BM, Eshraghi Y, Vaid S, Valimahomed AK, Shah JR, Smith GL, Finneran JJ, Shah NN, Guirguis MN, Eckmann MS, Antony AB, Ohlendorf BJ, Gupta M, Gilbert JE, Wongsarnpigoon A, Boggs JW. Randomized Placebo-Controlled Trial of 60-Day Percutaneous Peripheral Nerve Stimulation Treatment Indicates Relief of Persistent Postoperative Pain, and Improved Function After Knee Replacement. *Neuromodulation.* 2024 Jul;27(5):847-861.
26. Hatheway J, Hersel A, Song J, Engle M, Gutierrez G, Khemlani V, Kapural L, Moore G, Ajakwe R, Trainor D, Hah J, Staats PS, Lynch P, Makous J, Heit G, Kottalgi S, Desai MJ. Clinical study of a micro-implantable pulse generator for the treatment of peripheral

- neuropathic pain: 3-month and 6-month results from the COMFORT-randomised controlled trial. *Reg Anesth Pain Med*. 2024a May 31:rapm-2023-105264.
27. Hatheway J, Hersel A, Engle M, Gutierrez G, Khemlani V, Kapural L, Moore G, Ajakwe R, Trainor D, Hah J, Staats PS, Makous J, Heit G, Kottalgi S, Desai MJ; COMFORT Study Group. Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 12-month results from the COMFORT-randomized controlled trial. *Reg Anesth Pain Med*. 2024b Nov 20:rapm-2024-106099.
 28. Hatheway JA, Ratino T, Swain AR, Ratino T, Latif U, et al. Long-term pain relief delivered by micro-implantable pulse generator: findings from a large-scale, real-world data peripheral nerve stimulation patient registry. *Chron Pain Manag*. 2025;9:169. doi:10.29011/2576-957X.100069.
 29. Helm S, Shirsat N, Calodney A, Abd-Elsayed A, Kloth D, Soin A, Shah S, Trescot A. Peripheral Nerve Stimulation for Chronic Pain: A Systematic Review of Effectiveness and Safety. *Pain Ther*. 2021 Dec;10(2):985-1002.
 30. Huang AJ, Yull D, Yau YH, Selby M, Craig K, Bass T, Fish S, Murphy P, Clausen E, Whittle IR. A Clinical Care Pathway for Patients With Chronic Mechanical Low Back Pain Having Restorative Neurostimulation for Multifidus Muscle: Description, Patient Compliance, Clinical Outcomes, and Satisfaction in the First Two Years. *Neuromodulation*. 2025 Jun;28(4):558-566. doi: 10.1016/j.neurom.2024.12.004. Epub 2025 Jan 20. PMID: 39831866.
 31. International Neuromodulation Society (INS). Peripheral nerve stimulation. Reviewed Jul 6, 2019. Accessed Dec 19, 2025. Available at URL address: <http://www.neuromodulation.com/PNS>
 32. Ishak B, Campos B, Brunn H, Unterberg AW, Ahmadi R. Feasibility, Safety, and Efficacy of Subcutaneous Peripheral Nerve Field Stimulation for the Treatment of Refractory Low Back Pain: A Two-year Single-center Study. *Neuroscience*. 2018 Sep 1;387:38-47.
 33. Latif U, Moghim R, Valimahomed A, Lam CM, Abd-Elsayed A, Gulati A, Aman MM, Desai MJ, Dickerson DM, Tieppo Francio V, Gilmore C, Gish B, Hah JM, Hunter C, Ilfeld BM, Kalia H, Lester D, Li S, Mata R, Naidu R, Ottestad E, Pritzlaff SG, Schatman ME, Sheth SJ, Slavin KV, Suvar T, Yalamuru B, Staats PS, Sayed D, Deer TR. Consensus Guidelines for the Use of Peripheral Nerve Stimulation in the Treatment of Chronic Pain and Neurological Diseases: A Neuron Project from the American Society of Pain and Neuroscience. *J Pain Res*. 2025 Nov 7;18:5949-5990. doi: 10.2147/JPR.S537222. PMID: 41245476; PMCID: PMC12614495.
 34. Lorio MP, Lewandrowski KU, Lavelle W, Essig DA, Yue J, Ratliff J, DiGiorgio A, Kube R, Radcliff K, Shaffrey CI. ISASS Recommendations and Coverage Criteria for Restorative Neurostimulation for Multifidus Dysfunction, Lumbar Region: Coverage Indications, Limitations, and/or Medical Necessity-An ISASS 2025 Guideline Update. *Int J Spine Surg*. 2025 Dec 10:8833. doi: 10.14444/8833. Epub ahead of print. PMID: 41371946.
 35. Lorio M, Lewandrowski KU, Coric D, Phillips F, Shaffrey CI. International Society for the Advancement of Spine Surgery Statement: Restorative Neurostimulation for Chronic Mechanical Low Back Pain Resulting From Neuromuscular Instability. *Int J Spine Surg*. 2023 Oct;17(5):728-750.

36. Lucas JW, Connor EM, Bose J. Back, lower limb, and upper limb pain among U.S. adults, 2019. NCHS data brief, no 415. Hyattsville, MD: National Center for Health Statistics. Jul 2021.
37. Lucas JW and Sohi I. Chronic pain and high-impact chronic pain in U.S. adults, 2023. NCHS data brief, no 518. Hyattsville, MD: National Center for Health Statistics. Nov 2024.
38. Mainstay Medical. ReActiv8®. © 2026. Accessed Jan 7, 2026. Available at URL address: <https://mainstaymedical.com/physicians/>
39. Manchikanti L, Khaira MB, Soin A, Kaye AD, Knezevic NN, Abd-Elseyed A, Sanapati M, Manocha VA, Hirsch JA. Effectiveness of Peripheral Nerve Stimulation in Managing Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Pain Physician*. 2025 Sep;28(5):E481-E507. PMID: 40986902.
40. Manchikanti L, Sanapati MR, Soin A, Kaye AD, Kaye AM, Solanki DR, Chen GH, Nampiaparampil D, Knezevic NN, Christo P, Bautista A, Karri J, Shah S, Helm Ii S, Navani A, Wargo BW, Gharibo CG, Rosenblum D, Luthra K, Patel KG, Javed S, Reuland W, Gupta M, Abd-Elseyed A, Limerick G, Pasupuleti R, Schwartz G, Chung M, Slavin KV, Pampati V, Hirsch JA. Comprehensive Evidence-Based Guidelines for Implantable Peripheral Nerve Stimulation (PNS) in the Management of Chronic Pain: From the American Society Of Interventional Pain Physicians (ASIPP). *Pain Physician*. 2024 Nov;27(S9):S115-S191.
41. McRoberts WP, Wolkowitz R, Meyer DJ, Lipov E, Joshi J, Davis B, et al. Peripheral nerve field stimulation for the management of localized chronic intractable back pain: results from a randomized controlled study. *Neuromodulation*. 2013 Nov-Dec;16(6):565-74; discussion 574-5.
42. Mitchell B, Deckers K, De Smedt K, Russo M, Georgius P, Green M, et al. Durability of the Therapeutic Effect of Restorative Neurostimulation for Refractory Chronic Low Back Pain. *Neuromodulation*. 2021 Aug;24(6):1024-1032.
43. Mitchell B, Verrills P, Vivian D, DuToit N, Barnard A, Sinclair C. Peripheral Nerve Field Stimulation Therapy for Patients With Thoracic Pain: A Prospective Study. *Neuromodulation*. 2016 Oct;19(7):752-759.
44. Oswald J, Shahi V, Chakravarthy KV. Prospective case series on the use of peripheral nerve stimulation for focal mononeuropathy treatment. *Pain Manag*. 2019 Nov;9(6):551-558.
45. Petersen EA, Slavin KV. Peripheral nerve/field stimulation for chronic pain. *Neurosurg Clin N Am*. 2014 Oct;25(4):789-97.
46. Reverberi C, Dario A, Barolat G, Zuccon G. Using Peripheral Nerve Stimulation (PNS) to Treat Neuropathic Pain: A Clinical Series. *Neuromodulation*. 2014 Feb 14 [Epub ahead of print].
47. Sayed D, Grider J, Strand N, Hagedorn JM, Falowski S, Lam CM, Tieppo Francio V, Beall DP, Tomycz ND, Davanzo JR, Aiyer R, Lee DW, Kalia H, Sheen S, Malinowski MN, Verdolin M, Vodapally S, Carayannopoulos A, Jain S, Azeem N, Tolba R, Chang Chien GC, Ghosh P, Mazzola AJ, Amirdelfan K, Chakravarthy K, Petersen E, Schatman ME, Deer T. The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of

Interventional Treatments for Low Back Pain. *J Pain Res.* 2022 Dec 6;15:3729-3832.
Erratum in: *J Pain Res.* 2022 Dec 24;15:4075-4076.

48. Schwab F, Mekhail N, Patel KV, Langhorst M, Heros RD, Gentile J, Costandi S, Moore G, Gilmore C, Manion S, Chakravarthy K, Meyer SC, Bundy JV, Tate JL, Sanders R, Vaid S, Szentirmai O, Goree J, Patel VV, Lehmen J, Desai MJ, Pope JE, Giuffrida A, Hayek S, Virk SS, Paicius R, Klemme WR, Levy R, Gilligan C; RESTORE investigators. Restorative Neurostimulation Therapy Compared to Optimal Medical Management: A Randomized Evaluation (RESTORE) for the Treatment of Chronic Mechanical Low Back Pain due to Multifidus Dysfunction. *Pain Ther.* 2025 Feb;14(1):401-423.
49. Slavin KV. Peripheral nerve stimulation. In: Arle JE. *Essential Neuromodulation.* 2nd Ed. Cambridge, MA: Elsevier, Inc; 2022. 103-116.
50. Strand N, D'Souza RS, Hagedorn JM, Pritzlaff S, Sayed D, Azeem N, Abd-Elsayed A, Escobar A, Huntoon MA, Lam CM, Deer TR. Evidence-Based Clinical Guidelines from the American Society of Pain and Neuroscience for the Use of Implantable Peripheral Nerve Stimulation in the Treatment of Chronic Pain. *J Pain Res.* 2022 Aug 23;15:2483-2504.
51. Thomson S, Chawla R, Love-Jones S, Sharma M, Vajramani G, Williams A, et al.; ReActiv8 PMCF Investigators. Restorative Neurostimulation for Chronic Mechanical Low Back Pain: Results from a Prospective Multi-centre Longitudinal Cohort. *Pain Ther.* 2021 Dec;10(2):1451-1465.
52. Thomson S, Williams A, Vajramani G, Sharma M, Love-Jones S, Chawla R, Eldabe S. 5-year longitudinal follow-up of patients treated for chronic mechanical low back pain using restorative neurostimulation. *Reg Anesth Pain Med.* 2025 Aug 14:rapm-2025-106899. doi: 10.1136/rapm-2025-106899. Epub ahead of print. PMID: 40813075.
53. Thomson S, Williams A, Vajramani G, Sharma M, Love-Jones S, Chawla R, Eldabe S. Restorative neurostimulation for chronic mechanical low back pain - Three year results from the United Kingdom post market clinical follow-up registry. *Br J Pain.* 2023 Oct;17(5):447-456.
54. U.S Food and Drug Administration (FDA). Center for Devices and Radiologic Health (CDRH). 510(k) Premarket Notification database. Product codes GZF, NHI, QLK. Page last updated: Dec 22, 2025. Accessed Dec 22, 2025. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>
55. U.S Food and Drug Administration (FDA). Center for Devices and Radiologic Health (CDRH). Premarket Approval (PMA) database. Product codes GZF, NHI, QLK. Page last updated: Jan 5, 2026. Accessed Jan 12, 2026. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
56. Verrills P, Vivian D, Mitchell B, Barnard A. Peripheral nerve field stimulation for chronic pain: 100 cases and review of the literature. *Pain Med.* 2011 Sep;12(9):1395-405.
57. Wilson RD, Gunzler DD, Bennett ME, Chae J. Peripheral Nerve Stimulation Compared to Usual Care for Pain Relief of Hemiplegic Shoulder Pain: A Randomized Controlled Trial. *Am J Phys Med Rehabil.* 2014 Jan; 93(1): 17-28.

58. Wilson RD, Knutson JS, Bennett ME, Chae J. The Effect of Peripheral Nerve Stimulation on Shoulder Biomechanics: A Randomized Controlled Trial in Comparison to Physical Therapy. *Am J Phys Med Rehabil.* 2017 Mar;96(3):191-198.
59. Wilson RD, Harris MA, Gunzler DD, Bennett ME, Chae J. Percutaneous peripheral nerve stimulation for chronic pain in subacromial impingement syndrome: a case series. *Neuromodulation.* 2014 Dec;17(8):771-6; discussion 776.
60. Xu J, Sun Z, Wu J, Rana M, Garza J, Zhu AC, Chakravarthy KV, Abd-Elsayed A, Rosenquist E, Basi H, Christo P, Cheng J. Peripheral Nerve Stimulation in Pain Management: A Systematic Review. *Pain Physician.* 2021 Mar;24(2):E131-E152.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	<ul style="list-style-type: none"> No clinical policy statement changes. 	3/15/2026
Annual Review	<ul style="list-style-type: none"> No clinical policy statement changes. 	5/15/2025
Annual Review	<ul style="list-style-type: none"> Revised policy statement for peripheral nerve stimulation. 	3/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.